COMMUNIQUÉS West-GlobeNewswire

Entourage Health Introduces New Product Launches and Expands Market Reach of Leading Brand Dime Bag®
08/05/2024
Entourage Unveils Exciting New Product Offerings Diversifying the Company’s Signature Brands Dime Bag ® Widens Reach: Popular Offerings Now Across Alberta TORONTO, May 08, 2024 (GLOBE NEWSWIRE) -- Entourage Health Corp [...]
STRATA Skin Sciences to Report First Quarter 2024 Financial Results on May 15, 2024 and Provide Corporate Update
08/05/2024
HORSHAM, Penn., May 08, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative [...]
Ocean Drive Plastic Surgery's Dr. Alan Durkin to Present Clinical Research on Bellafill at the 12th Chinese Annual Meeting of Minimally-Invasive Aesthetic Medicine
08/05/2024
VERO BEACH, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- Ocean Drive Plastic Surgery proudly announces that Dr. Alan Durkin, MD, distinguished dual board-certified Plastic and Reconstructive Surgeon, will be joining Suneva [...]
Jnana Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
08/05/2024
BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Jnana Therapeutics , a clinical-stage biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for challenging-to-drug targets, today [...]
USARAD, Nanox’s Teleradiology Subsidiary, Awarded Accreditation from The Joint Commission
08/05/2024
Company earns Gold Seal of Approval® for Ambulatory Health Care Accreditation PETACH TIKVA, Israel, May 08, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical [...]
Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease
08/05/2024
CHARLOTTESVILLE, Va., May 08, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta [...]
Cue Biopharma to Present at the 20th Annual PEGS Boston Summit
08/05/2024
BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, [...]
Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)
08/05/2024
Findings demonstrate ability of PM359 to correct disease-causing mutation in CGD patient blood stem cells, leading to restored immune function in vivo with no off-target edits detected IND for PM359 recently cleared by [...]
Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
08/05/2024
Company to present poster at American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2024 highlighting initial results from its Phase 1 clinical trial of Decoy20 NEW YORK, May 08, 2024 (GLOBE NEWSWIRE [...]
Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights
08/05/2024
Data from long-term extension of Phase 2 VISIONARY-MS clinical trial of CNM-Au8 ® demonstrated significant evidence of repair and remyelination across multiple paraclinical endpoints (change from original baseline, p [...]
Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results
08/05/2024
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Belite Bio , Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases [...]
Recce Pharmaceuticals Granted New Patent in China for RECCE® Anti-Infectives
08/05/2024
SYDNEY, Australia, May 08, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd. (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced the China National Intellectual [...]
Rakovina Therapeutics Announces Extensions and Expansions of Strategic Collaborations to Support AI Research
08/05/2024
Expanded Activities Position Rakovina Therapeutics to Capitalize on AI Partnerships with The University of British Columbia and Pharma Inventor Inc. VANCOUVER, British Columbia, May 08, 2024 (GLOBE NEWSWIRE) -- Rakovina [...]
Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wednesday, May 15, 2024
08/05/2024
CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare [...]
BioAtla to Participate in the Citizens JMP Life Sciences Conference
08/05/2024
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the [...]
Keros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
08/05/2024
LEXINGTON, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel [...]
Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology
08/05/2024
― Phase 2b ReDUX4 clinical trial indicates improvements in functional, structural, and patient-reported outcomes; findings informed the design and choice of efficacy endpoints in the ongoing Phase 3 clinical trial― ― [...]
ONCOTELIC PRESENTING AT BIOPHARMA NEXUS CONFERENCE SAN DIEGO 2024
08/05/2024
AGOURA HILLS, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its presentation at Biopharma Nexus Conference. Dr. Andy Hu, Nanomedicine Manager, will be presenting: [...]
Intra-Cellular Therapies to Participate in Two Upcoming Investor Conferences
08/05/2024
NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) [...]

Pages